You are here
Anteana Therapeutics Inc
UEI: N/A
# of Employees: 1
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Peripheral FAAH as a target for novel analgesics
Amount: $1,498,471.00DESCRIPTIONprovided by applicantPain management is a significant unmet medical needAnandamide is an endocannabinoid mediator that plays important roles in the regulation of painPrevious work has shown ...
STTRPhase II2017Department of Health and Human Services National Institutes of Health -
NAAA Inhibitors for pain and inflammation
Amount: $223,903.00DESCRIPTION provided by applicant Chronic pain management accounts for approximately US$ billion in direct and indirect costs Current treatments fail to address effectively this large medical p ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health -
A new treatment for NSAID-associated gastrointestinal damage
Amount: $150,000.00DESCRIPTION provided by applicant Non steroidal anti inflammatory drugs NSAIDs are among the most widely consumed pharmaceuticals but their prolonged use causes gastric injury and damage to the ...
STTRPhase I2015Department of Health and Human Services National Institutes of Health -
Peripheral FAAH as a target for novel analgesics
Amount: $132,661.00DESCRIPTION (provided by applicant): Pain management remains a significant unmet medical need. Anandamide is an endogenous marijuana-like ('endocannabinoid') molecule that plays important ro ...
STTRPhase I2013Department of Health and Human Services National Institutes of Health